• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Physiology and Biochemistry >Urinary and Blood MicroRNA-126 and -770 are Potential Noninvasive Biomarker Candidates for Diabetic Nephropathy: a Meta-Analysis
【24h】

Urinary and Blood MicroRNA-126 and -770 are Potential Noninvasive Biomarker Candidates for Diabetic Nephropathy: a Meta-Analysis

机译：尿液和血液MicroRNA-126和-770是糖尿病性肾病的潜在非侵入性生物标志物候选者：一项荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims Diabetic nephropathy (DN), a major diabetic microvascular complication, has a long and growing list of biomarkers, including microRNA biomarkers, which have not been consistent across preclinical and clinical studies. This meta-analysis aims to identify significant blood- and urine-incident microRNAs as diagnostic/prognostic biomarker candidates for DN. Methods PubMed, Web of Science, and Cochrane Library were searched from their earliest records through 12th Dec 2016. Relevant publications for the meta-analysis included (1) human participants; (2) microRNAs in blood and urine; (3) DN studies; and (4) English language. Four reviewers, including two physicians, independently and blindly extracted published data regarding microRNA profiles in blood and/or urine from subjects with diabetic nephropathy. A random-effect model was used to pool the data. Statistical associations between diabetic nephropathy and urinary or blood microRNA expression levels were assessed. Results Fourteen out of 327 studies (n=2,747 patients) were selected. Blood or urinary microRNA expression data of diabetic nephropathy were pooled for this analysis. The hsa-miR-126 family was significantly (OR 0.57; 95% CI 0.44-0.74; p-value < 0.0001) downregulated in blood from patients with diabetic kidney disease, while its urinary level was upregulated (OR 2931.12; 95% CI 9.96-862623.21; p-value = 0.0059). The hsa-miR-770 family microRNA were significantly (OR 10.24; 95% CI 2.37-44.25; p-value = 0.0018) upregulated in both blood and urine from patients with diabetic nephropathy. Conclusions Our meta-analysis suggests that hsa-miR-126 and hsa-miR-770 family microRNA may have important diagnostic and pathogenetic implications for DN, which warrants further systematic clinical studies.
机译：背景/目的糖尿病肾病（DN）是一种主要的糖尿病微血管并发症，其生物标志物（包括microRNA生物标志物）的清单越来越长，在临床前和临床研究中并不一致。这项荟萃分析旨在鉴定出大量发生血液和尿液的微小RNAs作为DN的诊断/预后生物标志物候选物。方法检索从PubMed，Web of Science和Cochrane图书馆到2016年12月12日的最早记录。荟萃分析的相关出版物包括（1）人类参与者; （2）血液和尿液中的microRNA; （3）DN研究; （4）英语。包括两名医生在内的四名审稿人独立且盲目地从糖尿病肾病患者的血液和/或尿液中提取了有关微RNA谱的公开数据。使用随机效应模型来汇总数据。评估了糖尿病肾病与尿液或血液中microRNA表达水平之间的统计关联。结果从327项研究中选择了14项（n = 2,747例患者）。合并糖尿病肾病的血液或尿microRNA表达数据用于该分析。糖尿病肾病患者血液中的hsa-miR-126家族显着下调（OR 0.57; 95％CI 0.44-0.74; p值＆＃x3c; 0.0001），而其尿液水平上调（OR 2931.12; 95 ％CI 9.96-862623.21; p值= 0.0059）。糖尿病肾病患者的血液和尿液中的hsa-miR-770家族微RNA均显着上调（OR 10.24; 95％CI 2.37-44.25; p值= 0.0018）。结论我们的荟萃分析表明，hsa-miR-126和hsa-miR-770家族microRNA可能对DN具有重要的诊断和致病意义，因此有必要进行进一步的系统临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号